Lavinia Petriaggi

Lavinia Petriaggi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
LPLavinia Petriaggi
Lavinia Petriaggi
EGEmanuele Giorgio
Emanuele Giorgio
GNGiuseppe Natali
Giuseppe Natali
CGCristiana Galeano
Cristiana Galeano
SFSimão Rodrigues Furtado
Simão Rodrigues Furtado
Anna Martina BattagliaAnna Martina Battaglia
Anna Martina Battaglia
Epithelial ovarian cancer (EOC) is a highly lethal gynecological malignancy characterized by frequent late-stage diagnosis, high rates of chemoresistance, and poor long-term survival. Emerging evidence underscores the central role of iron metabolism dysregulation in EOC pathogenesis, progression, and treatment resistance. Ovarian cancer cells and cancer stem cells exhibit an “iron-addicted” phenotype, characterized by increased iron uptake, reduced export, and enhanced storage, which sustains proliferative signaling, redox imbalance, and metastatic potential. Recent advances have illuminated ferroptosis, a regulated form of iron-dependent cell death driven by lipid peroxidation, as a promising therapeutic target for overcoming resistance to platinum-based chemotherapy. This review provides a comprehensive synthesis of the mechanisms governing iron metabolism and ferroptosis in EOC, with a particular focus on Class IV ferroptosis inducers (FINs). These agents act by disrupting iron homeostasis and promoting labile iron pool accumulation, thereby triggering oxidative stress and ferroptotic death. Preclinical studies demonstrate that Class IV FINs, including iron nitroprusside, superparamagnetic iron oxide nanoparticles, ferric ammonium citrate, and Ferlixit, exhibit potent antitumor activity in EOC models, particularly in chemoresistant and stem-like tumor subpopulations. Furthermore, Class IV FINs show synergistic effects when combined with other ferroptosis modulators or immunotherapeutic agents. Despite their promise, clinical translation remains limited by challenges in bioavailability, delivery specificity, and potential systemic toxicity. Ongoing efforts in nanotechnology, biomarker discovery, and tumor stratification offer new avenues for refining ferroptosis-based interventions. Ultimately, this review highlights Class IV FINs as a mechanistically distinct and clinically actionable strategy to target metabolic vulnerabilities in EOC, with the potential to reshape therapeutic paradigms and improve patient outcomes.

18 March 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
EGEmanuele Giorgio
Emanuele Giorgio
CGCristiana Galeano
Cristiana Galeano
GNGiuseppe Natali
Giuseppe Natali
LPLavinia Petriaggi
Lavinia Petriaggi
MFM Concetta Faniello Faniello
M Concetta Faniello Faniello
FBFlavia Biamonte
Flavia Biamonte
Psoriasis is classically defined as an immune-mediated disease. However, many patients do not achieve durable remission after immune-targeted therapies, suggesting that further pathogenic mechanisms may contribute to the persistence of psoriasis. Here, we propose ferroptosis, an iron-dependent regulated cell death driven by lipid peroxidation and failure of lipid repair, as a potential link between metabolic stress and immune-mediated inflammation in psoriasis. We summarize experimental evidence showing that membrane lipids remodeling, antioxidant suppression, lipid peroxidation, and dysregulated iron handling together define ferroptosis-permissive niches within psoriatic lesions. We also discuss functional studies demonstrating that ferroptosis modulation can reshape psoriasiform inflammation and explore how ferroptotic stress may amplify inflammatory signaling at the immune-epidermal interface, reinforcing IL-17/TNF/IFN-γ pathways. Finally, we discuss ferroptosis-related transcriptomic signatures as a potential approach to stratify psoriasis, capturing metabolic features that are not reflected by cytokine profiling. The translational opportunities and constraints for ferroptosis-targeted interventions are outlined, highlighting epidermal redox homeostasis as a new therapeutic frontier in psoriasis.

1 January 2025 in Ferroptosis and Oxidative Stress
Verified
Journal Article
Open access
PDF file
FBFlavia Biamonte
Flavia Biamonte
GNGiuseppe Natali
Giuseppe Natali
CGCristiana Galeano
Cristiana Galeano
RLRosaria Lamanna
Rosaria Lamanna
LPLavinia Petriaggi
Lavinia Petriaggi
Anna Martina BattagliaAnna Martina Battaglia
Anna Martina Battaglia
Ovarian cancer remains the most lethal gynaecological malignancy, due to late diagnosis, extensive peritoneal dissemination, and the common emergence of therapy resistance. While intrinsic genomic instability and DNA repair defects have long been considered the main biological events underlying ovarian cancer pathogenesis, it is now evident that disease progression is critically shaped by the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute the main immune population in both solid lesions and malignant ascites, orchestrating tumor growth, metastatic dissemination, immune evasion, and chemoresistance. In parallel, ferroptosis, an iron-dependent, lipid peroxidation-driven form of regulated cell death, has emerged as a therapeutic vulnerability in ovarian cancer, particularly in platinum- and Poly (ADP-ribose) polymerase (PARP) inhibitor-resistant disease. TAMs and ferroptosis engage in a bidirectional and context-dependent crosstalk: TAMs iron handling, redox activity, and polarization states modulate ferroptotic sensitivity of ovarian cancer cells, while ferroptotic stress reshapes TAMs phenotype, cytokine release, and immunosuppressive capacity. In this review, we reframe ovarian cancer as an immune-metabolic disease in which ferroptosis and TAM biology form a tightly coupled regulatory axis. We synthesize current mechanistic insights and propose that effective therapeutic ferroptosis induction requires concurrent modulation of TAMs plasticity.

26 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EGEmanuele Giorgio
Emanuele Giorgio
CGCristiana Galeano
Cristiana Galeano
GNGiuseppe Natali
Giuseppe Natali
LPLavinia Petriaggi
Lavinia Petriaggi
MFM Concetta Faniello Faniello
M Concetta Faniello Faniello
FBFlavia Biamonte
Flavia Biamonte
Psoriasis is classically framed as an IL-23/IL-17/TNF-driven immune disease, yet durable remission remains elusive for many patients, suggesting that epidermal-intrinsic pathogenic mechanisms shape chronicity and therapeutic escape. Here we propose ferroptosis, viewed as iron-dependent membrane lipid peroxidation coupled to failure of lipid repair, as a unifying, epidermis-centered axis that links metabolic stress to immune amplification in psoriasis. In this review, we synthesize experimental evidence showing that GPX4 suppression, lipid peroxidation accumulation, dysregulated iron handling and PUFA-remodeling programs, together define ferroptosis-permissive niches in psoriatic plaques. We also integrate functional studies demonstrating that ferroptosis modulation reshapes psoriasiform inflammation and discuss why ferroptotic stress can act as a feed-forward amplifier at the immune-epidermal interface, reinforcing IL-17/TNF/IFN-γ circuits and myeloid-Th17 crosstalk. Finally, we highlight ferroptosis-related transcriptomic signatures as a stratification layer that captures metabolic heterogeneity beyond cytokine profiling, with implications for relapse and incomplete response to existing therapies. The translational opportunities and constraints for ferroptosis-targeted interventions are outlined, advocating precision normalization of epidermal redox homeostasis as a new therapeutic frontier in psoriasis.